Aug. 10 at 9:10 PM
$ABCL If the 12-week data preserve efficacy, Phase III design is agreed with FDA without complications, and liver safety remains clean, I think a rerating into the
$20–25 range before approval becomes quite plausible. Actual approval with genuinely best-in-class Phase III data could eventually justify a valuation well above
$25, particularly because ABCL would then also have validated its broader internal drug-development platform.
